Department of Medical Oncology, Institut Paoli-Calmettes, European Neuroendocrine Tumor Society (ENETS) Center of Excellence, Institut Paoli-Calmettes Neuroendocrine Tumor (IPC NET) Center, Marseille, France.
Department of Biopathology, Institut Paoli-Calmettes, European Neuroendocrine Tumor Society (ENETS) Center of Excellence, Institut Paoli-Calmettes Neuroendocrine Tumor (IPC NET) Center, Marseille, France.
Front Endocrinol (Lausanne). 2022 Apr 19;13:860614. doi: 10.3389/fendo.2022.860614. eCollection 2022.
Malignant insulinomas are functional neuroendocrine tumors of the pancreas and the primary cause of tumor-related hypoglycemia. Malignant insulinoma is rare and has a poor prognosis. We report a case of metastatic malignant insulinoma in a 64-year-old female patient with severe and refractory hypoglycemia. After several ineffective locoregional and systemic therapeutic lines for the secretory disease, the introduction of pasireotide, a second-generation somatostatin analog, provided an improved clinical and secretory evolution both quickly and sustainably, with an excellent safety profile. Pasireotide is an effective and well-tolerated therapy in the treatment of refractory hypoglycemia in metastatic insulinoma.
恶性胰岛素瘤是胰腺的功能性神经内分泌肿瘤，也是与肿瘤相关的低血糖的主要原因。恶性胰岛素瘤较为罕见，预后较差。我们报告了一例 64 岁女性患者的转移性恶性胰岛素瘤病例，该患者患有严重且难治性低血糖症。在对该分泌性疾病进行了几次无效的局部和全身治疗方案后，引入第二代生长抑素类似物培高利特（pasireotide）可快速且持续地改善临床和分泌情况，且安全性良好。培高利特在治疗转移性胰岛素瘤引起的难治性低血糖方面是一种有效且耐受良好的治疗方法。
